Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo treatments capable of precisely and durably engineering the hematopoietic system, today announced the U.S ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Ensoma Inc.’s lead program, EN-374, has been granted orphan drug and rare pediatric disease designations by the FDA for the ...

Ensoma's lead program, EN-374, has been granted a pair of FDA designations for the treatment of X-linked chronic granulomatous disease. Both rare pediatric disease and orphan drug designations from ...

These structures may be destroyed by systemic autoimmune disorders as well as by granulomatous diseases. To prohibit permanent damage of hair follicles, early diagnosis and the correct treatment ...

In vivo HSC-directed therapy advancing to IND filing in H1 2025 for treatment of X-linked chronic granulomatous disease (X-CGD) BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company advancing ...

Around 1.5 million patients succumb to the disease caused by the bacterium Mycobacterium tuberculosis (Mtb). The novel ...

Crohn's disease is part of a group of conditions ... surgery may be necessary. Crohn’s (granulomatous) colitis affects only the colon. If you have this type, you may be more likely to have ...

As the authors discuss, at least some of the highlighted exposures have been linked to granulomatous disease in adults, giving biological plausibility to their findings. However, there does appear to ...

An expert review provides best practice advice on diagnostic considerations of immune-mediated disorders that should be ...